Now I have a thorough understanding of the paper. Let me construct the consolidated review.

## Summary

This paper introduces a composite framework for personalized longitudinal prediction of brain volumetric/biomarker trajectories. The method combines a population-level Deep Kernel GP (p-DKGP) trained on large cohorts with a subject-specific Deep Kernel GP (ss-DKGP) fine-tuned on an individual's observed data. The key novelty is an **adaptive shrinkage estimation** technique that learns (via XGBoost) an optimal blending parameter $\alpha$ as a function of predictive means, variances, and observation time, balancing population trends against individual deviations. The method is evaluated on 6 brain ROIs and two SPARE biomarkers, with external validation on three independent clinical studies (AIBL, OASIS, PreventAD).

---

## Strengths

1. **Novel adaptive shrinkage estimation via learned function (Sections 2.5–2.7).** The paper introduces a principled approach to learning the shrinkage parameter $\alpha$ as a function of $q = \{y_p, y_s, v_p, v_s, T_{\text{obs}}\}$ using XGBoost, rather than using a fixed heuristic. The ablation study (Table 1, Section 3.6) demonstrates that this learned approach outperforms both constant $\alpha$ and a deterministic optimization over observed data — a genuinely informative empirical finding.

2. **Strong generalization across multiple external clinical studies (Section 3.5).** The method is validated on three independent datasets (AIBL, OASIS, PreventAD) with different demographics and follow-up intervals. pers-DKGP achieves lower Mean AE with narrow confidence intervals in all three (e.g., Mean AE $0.139 \pm 0.004$ in PreventAD), providing a demanding test of generalizability beyond the training population.

3. **Handles irregularly spaced longitudinal data without requiring equal time intervals.** The paper explicitly distinguishes itself from prior work (Rudovic et al., 2019) by noting that it "does not require equal time intervals" and "utilize[s] all the available longitudinal information across subjects even in the presence of temporal unalignment" (Introduction). This is a practical advantage for real-world clinical data where follow-up times are irregular.

4. **Comprehensive interpretability and ablation analysis (Section 3.6, Supplementary D.3).** SHAP analysis reveals that $T_{\text{obs}}$ (observation time) is the most influential variable in predicting $\alpha$, and the learned $\alpha$ consistently decreases as more observations become available. This provides transparency into the model's decision process and aligns with clinical intuition — the more data one has on a subject, the more weight is given to their specific trajectory.

5. **Application to composite neuroimaging biomarkers (SPARE-AD, SPARE-BA) beyond individual ROIs (Section 3.4).** The method generalizes to machine-learning-derived biomarkers, achieving lower MAE across diagnostic groups including AD subjects with steep nonlinear trends that traditional methods like LMM fail to capture.

---

## Weaknesses

### Fatal
None.

### Major

1. **Unjustified independence assumption in posterior correction (Section 2.4) affects the validity of the reported UQ evaluation.** The combined variance is computed as $v_c = \alpha^2 v_p + (1-\alpha)^2 v_s$, which follows from assuming p-DKGP and ss-DKGP predictions are independent. This is likely violated because both models share the same transformation function $\Phi$ (learned from the population), and the ss-DKGP is initialized from the population model. Their predictions will be correlated. The paper acknowledges this limitation in the Discussion and notes it "affects only the uncertainty quantification and leaves the posterior-corrected predictive mean unaffected." While the predictive mean claims survive, the paper's uncertainty quantification evaluation (coverage, interval width) rests on an incorrect probabilistic formulation, and the paper does not quantify how large the error is or provide corrected intervals. Given that UQ evaluation is highlighted in the abstract and evaluation section, this is a significant gap.

2. **Missing comparison to the most directly relevant personalized GP baseline (Rudovic et al., 2019).** The paper cites Rudovic et al. as proposing "a meta-weighting scheme to combine two personalized GP models" (Introduction) — a setup nearly identical in spirit. Yet Rudovic et al. are not included as a baseline. The only GP-related baseline is Deep Mixed Effects (Chung et al., 2019), which uses a different personalization mechanism (LSTM mean function). Without comparing to the most directly relevant prior work, it is impossible to assess whether the adaptive shrinkage strategy adds value over existing meta-weighting or domain-adaptive GP approaches. The paper's argument that the method differs (predicting at arbitrary future times, handling irregular intervals) could be strengthened by a direct empirical comparison showing these differences matter.

3. **Incomplete uncertainty quantification evaluation against baselines.** The paper emphasizes evaluating both predictive accuracy and uncertainty quantification (Section 3.2, defining coverage and interval width). However, the main results (Section 3.3, Figure 2, external validation in Section 3.5) report only MAE/Mean AE. No coverage or interval width numbers are reported for any baseline method (LMM, GAM, Deep Regression, DME). The reader cannot assess whether the proposed method produces better-calibrated or tighter intervals than alternatives. The ablation study (Table 1) only compares variants of the proposed method. Given that UQ is part of the paper's framing, this omission significantly weakens the evidence for that claimed contribution.

### Minor

1. **Limited ROI evaluation without justification.** Only 6 of the 145 available ROIs are used for the main evaluation (Section 3.3). While these are standard and clinically relevant ROIs for AD research (Hippocampus, Thalamus, Amygdala, Parahippocampal Gyrus, Lateral Ventricle), the paper provides no explicit justification for why these 6 were selected, raising a possible cherry-picking concern. The ablation (Section 3.6) adds a 7th ROI, and the supplement (Table 6) covers additional ROIs, but the main evaluation remains focused on a narrow subset. A principled selection criterion or aggregated results over all ROIs would substantially strengthen the evidence.

2. **Percentage-only reporting for main ROI comparison without absolute values.** In Section 3.3, the paper reports percentage MAE differences (e.g., 177.66% for AD subjects) between LMM and pers-DKGP without providing the corresponding absolute MAE values in the main text. While the percentage communicates relative improvement, absolute values are necessary to assess practical significance and to enable comparison with the external validation results (which are reported in absolute terms). Numerical tables in the main text would improve interpretability.

3. **MLP architecture details not provided in main text.** The transformation function $\Phi$ is described as a Multi-Layer Perceptron (Section 2.2), but the main text does not specify the number of layers, hidden units, or activation function. While these details may be in the supplement (Section C.3), key architectural parameters should be included or summarized in the main text for reproducibility.

### Trivial
None.

---

## Nice-to-Haves

- **UQ comparison to baselines** (coverage and interval width for LMM, GAM, Deep Regression, DME) would directly substantiate the uncertainty quantification claims.
- **Absolute numerical tables** for all metrics across all ROIs and baselines in the main text would improve interpretability over percentage-only reporting.
- **Discussion of computational cost** (training/inference time for DKGP models) would help assess practical applicability.
- **Quantification of the independence assumption error** (e.g., estimating correlation between $y_p$ and $y_s$ on validation data and showing it is small enough to ignore, or providing corrected coverage intervals) would strengthen the UQ evaluation.

---

## Removed Points

These points are flagged to be removed; treat them with caution.

- **"Section 2.6–2.7 truncation"** (harsh critic): The critic notes that Section 2.7 appears truncated. This is a text-extraction artifact (parser truncation); the original submission contains the complete section.
- **"Table 1 not visible"**: The placeholder image is a parser rendering issue; the original submission contains the full table.
- **"No justification for why 6 ROIs" framed as potential cherry-picking**: The criticism is retained in Minor but downweighted from the critic's framing, as the ROIs are standard AD-relevant structures and supplementary results cover additional ROIs.
- **"177.66% differences sound implausibly large"** (harsh critic): Percentage differences are a valid way to communicate relative improvement. The absolute values are partially available from the external validation section. This is weakened to a Minor point about wanting absolute values alongside percentages — not about the comparison being meaningless.

---

## Novel Insights

None beyond the paper's own contributions.

---

## Suggestions

1. **Address the independence assumption**: Either (a) estimate the correlation between $y_p$ and $y_s$ on validation data and show it is negligible, providing corrected coverage intervals, or (b) derive a combined variance that includes a cross-covariance term. Without this, the UQ evaluation cannot be taken at face value.

2. **Add Rudovic et al. (2019) as a baseline**: Directly comparing to the most closely related personalized GP method would test whether the adaptive shrinkage strategy provides measurable benefits over existing meta-weighting approaches, and would clarify the empirical advantages of the proposed framework (e.g., handling irregular intervals, predicting at arbitrary future times).

3. **Report UQ metrics (coverage, interval width) for all baseline methods**, not just for ablation variants of the proposed method. This would complete the UQ evaluation that the paper claims as part of its assessment.

4. **Provide absolute numerical values alongside percentage differences** in the main results (Section 3.3), ideally in a table, so that readers can assess effect sizes directly rather than inferring them from percentages.

5. **Justify the ROI selection** or report aggregated results across all 145 ROIs (mean/median AE across all ROIs) to dispel any concern about selective reporting.

---

## Score and Decision

The paper proposes a genuinely interesting approach — learning a data-driven shrinkage parameter to blend population and subject-specific deep kernel GP predictions — and presents strong generalization evidence across multiple external datasets. The method is well-motivated and the ablation/interpretability analysis adds useful insight.

However, the evidence is weakened by three significant gaps: (1) the independence assumption underlying the UQ evaluation is acknowledged but unaddressed, undermining the uncertainty quantification claims; (2) the most directly relevant personalized GP baseline (Rudovic et al., 2019) is not compared against; and (3) the paper's own UQ metrics (coverage, interval width) are never reported for baseline methods. These gaps prevent full substantiation of the claimed contributions. The core predictive accuracy results are promising, and the issues are fixable, but as presented the paper does not fully support its claims.

**Recommendation:** Major revisions required.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>